Expert: mAb targeting IL-23 p19 subunit. Same mechanism as risankizumab, different pharmacokinetics. Q8W maintenance. PASI 90 ~70-76% (slightly below risankizumab). Also approved for PsA and CD.

Everyday: Same approach as Skyrizi (blocking IL-23 to dissolve the inflammatory army) but a different antibody. Tremfya was first selective IL-23 blocker approved. Effective and durable, but trails Skyrizi slightly in efficacy and needs more frequent dosing (Q8W vs Q12W).

Targets: ["IL-23P19"]

Primary EP: [{"id":"pasi90-w16","name":"PASI 90 at Week 16","type":"PRIMARY","unit":"%","results":[{"value":73.3,"arm_id":"gus-arm","p_value":0.001},{"value":49.7,"arm_id":"ada-arm"},{"value":2.9,"arm_id":"pbo-ar

First selective IL-23 (p19) inhibitor approved (2017). VOYAGE 1/2 pivotal trials. PASI 90 70-73% Wk16, 76% Wk48. PASI 100 34-37% Wk16. Candidiasis <1%. Differentiated by native Fc region that binds CD64 on IL-23-producing myeloid cells (dual binding mechanism — anchors to source cells). Shorter half-life (~17d) and lower bioavailability (~49%) than Skyrizi requires q8w vs q12w dosing. J&J CEO projects $10B+ peak (Stelara-size or bigger) driven by IBD expansion. Approved: PsO (2017), PsA (2020), UC (2024), CD (2025). US LOE ~2031.

{"keyRisks":[{"category":"Infections","description":"Infections (TB), hypersensitivity, hepatotoxicity"}],"monitoring":["TB screening"],"labelSource":"FDA PI 2025","hasBoxedWarning":false}